Special Issue

Tuberculosis: From Pathogenesis to Targeted Therapies

Message from the Guest Editor

Most bacterial infections can quickly be cured by antibiotic monotherapy. In contrast, drug-sensitive tuberculosis (TB) must be treated with a combination of four antibiotics over 6 months. This lengthy, multidrug regimen often confounds compliance, leading to treatment failure, recurrence of TB, and the emergence of antibiotic-resistant mycobacteria. The goal of current TB research is, therefore, not only the development of new antibiotics and identification of novel antibiotic targets but also to find therapies that shorten treatment time. One reason for the need for such a long-term therapy is the development of centrally necrotizing granulomas in TB patients. New drugs and regimens for the therapy of TB must consider the pathogenesis of this complex disease, ensuring that compounds can reach their target and act more effectively within the habitat of centrally necrotizing granulomas. This Special Issue aims to cover new research on the pathogenesis of TB in terms of therapy and novel compounds, as well as present host-directed strategies that mediate better and faster antibiotic treatment through modulation of the pathology.

Guest Editor

Dr. Christoph Hölscher
Research Center Borstel - Leibniz Lung Center, Division of Infection Immunology, 23845 Borstel, Germany

Deadline for manuscript submissions

closed (31 August 2024)

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/143755

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).